Amyloidosis Market Report and Forecast 2025-2034

The amyloidosis market was valued at USD 4.35 Billion in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 6.40% during the forecast period of 2025-2034 and attain a market value of USD 8.09 Billion by 2034.

Amyloidosis Market Overview

Amyloidosis is a rare condition caused by the abnormal buildup of amyloid proteins in tissues and organs, leading to dysfunction and failure. Key growth drivers include rising prevalence among aging populations and advancements in specialized therapies. Major market trends involve expedited drug development along with the adoption of personalized medicine, and combination treatments. Moreover, rising R&D investments and regulatory incentives are reshaping the therapeutic landscape significantly.

Amyloidosis Market Growth Drivers

Rising Prevalence of Amyloidosis Drives Market Growth

The rising prevalence of systemic and localized amyloidosis, particularly among older adults, is a key growth driver. AL amyloidosis, representing 78% of cases, occurs at a rate of 1 case per 100,000 in Western countries, with approximately 1,275-3,200 new cases occurring annually in the United States. The increasing prevalence underscores the demand for improved diagnostics and novel treatments.

Amyloidosis Market Trends

Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:

Shift Towards Targeted Therapies

In December 2023, AstraZeneca and Ionis received US FDA approval for Wainua (eplontersen) to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Based on the NEURO-TTRansform Phase III trial, Wainua demonstrated reductions in serum transthyretin (TTR) levels, improved neuropathy impairment, and quality of life. As the first self-administered treatment via auto-injector, it addressed a significant unmet medical need. With regulatory reviews ongoing in Europe and other regions, Wainua is set to expand global market opportunities, driving growth in targeted therapies for rare diseases and offering innovative solutions for improved patient outcomes.

Rising Demand for Personalized Medicine to Fuel Amyloidosis Market Demand

Advances in genomics, proteomics, and biomarker identification are enabling tailored treatments based on individual genetic profiles and disease subtypes. Personalized therapies enhance efficacy, reduce side effects, and drive patient adoption, boosting market growth and fostering innovation in amyloidosis treatment.

Adoption of Combination Therapies Expected to Propel Amyloidosis Market Growth

Combination therapies, integrating chemotherapy with monoclonal antibodies, proteasome inhibitors, or immunomodulatory drugs, are improving treatment outcomes by reducing amyloid deposits and enhancing organ function. This strategy is gaining traction among healthcare providers, driving market growth.

Biomarker Advancements Likely to Revolutionize Amyloidosis Market

Innovations in biomarker technologies are transforming amyloidosis diagnosis and treatment by enabling early detection, disease monitoring, and precision therapies. Biomarker advancements (supported by AI and machine learning) improve clinical trial efficiency, reduce diagnostic delays, and accelerate market growth.

Amyloidosis Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
• AA Amyloidosis
• Others

Market Breakup by Treatment Type

• Targeted Therapy
• Chemotherapy
• Stem Cell Transplant
• Medication
• Transthyretin Transport Inhibitor
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Proteasome Inhibitors
• Others
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Academic and Research Institutes
• Others

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Amyloidosis Market Share

Market Segmentation Based on Route of Administration to Witness Substantial Market Growth

Based on the route of administration, the market is divided into oral, parenteral, and others. Among these, the oral administration is expected to lead the market. Oral medications, such as transthyretin stabilizers (e.g., Tafamidis), offer ease of use, reducing the need for hospital visits, high patient compliance, and cost-effectiveness. It allows for convenient at-home treatment. In addition, oral therapies provide a less invasive and more scalable option for long-term management, ensuring better patient adherence and improved outcomes.

Amyloidosis Market Analysis by Region

Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market due to its robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies. The research and development activities in the pharmaceutical and biotechnology sectors are also contributing to significant growth in the region.

Leading Players in the Amyloidosis Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Pfizer Inc

Established in 1849 and headquartered in New York, USA, Pfizer is one of the key pharmaceutical companies. It has developed Vyndamax (tafamidis), a breakthrough therapy for transthyretin amyloidosis (ATTR)-slowing down the progression of the disease and improving the survival rate in hereditary and wild-type ATTR patients.

Johnson & Johnson Services, Inc

Founded in 1886 and headquartered in New Jersey, USA, Johnson & Johnson is a major healthcare player. Its subsidiary, Janssen Pharmaceuticals, developed Daratumumab (Darzalex), a monoclonal antibody that targets plasma cells, thereby reducing amyloid protein production and effectively treating light-chain (AL) amyloidosis.

Takeda Pharmaceutical Company Limited

Takeda, based in Tokyo, Japan, is an international biopharmaceutical leader, founded in 1781. Its products for AL amyloidosis treatment include Ninlaro (ixazomib). It aims to be less invasive by providing an oral option to improve patients' outcomes in combination.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company, located in New York, USA, was established in 1887. It is focused on innovative therapies for people and engages in the development of immunomodulatory therapies and combination therapies for AL amyloidosis and utilizes its oncological and hematological experience to improve disease management and survival rates for patients.

Other companies include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Sanofi, Alnylam Pharmaceuticals, Inc., and Prothena.

Key Questions Answered in the Amyloidosis Market

• What was the amyloidosis market value in 2024?
• What is the amyloidosis market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is the market segmentation based on the type?
• What is the market breakup based on the treatment type?
• What is the market segmentation based on the route of administration?
• What is the market breakup based on the distribution channel?
• What is the market segmentation based on the end user?
• What are the major factors aiding the amyloidosis market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major amyloidosis market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the amyloidosis market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• What are the key treatment trends for AL amyloidosis?

This product will be delivered within 3-5 business days.